Format

Send to

Choose Destination
Pharmacogenomics. 2015;16(3):239-50. doi: 10.2217/pgs.14.166.

Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies.

Author information

1
Department of General Surgery, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China.

Abstract

AIM:

This study evaluated the relationships between IL-18 polymorphisms and tacrolimus elimination in Chinese liver transplant patients.

PATIENTS & METHODS:

Eighty-four liver transplant patients from Shanghai (training set) and 50 patients from Shandong (validating set) were inculded. IL-18 polymorphisms (rs5744247, rs7106524, rs549908, rs187238 and rs1946518) and CYP3A5 rs776746 were genotyped.

RESULTS:

In training set, daily drug dose, total bilirubin, donor CYP3A5 rs776746 and IL-18 rs5744247 genotypes were screened to construct prediction model for tacrolimus elimination. This model was confirmed in validating set (p < 0.001). Donor IL-18 rs5744247 polymorphism was an independent predictor of tacrolimus elimination in the first week after transplantation in both training (p = 0.008) and validating cohorts (p = 0.033).

CONCLUSION:

Donor IL-18 rs5744247 polymorphism may influence on tacrolimus elimination. Original submitted 16 July 2014; Revision submitted 12 November 2014.

KEYWORDS:

CYP3A5; IL-18; SNP; liver transplantation; tacrolimus

PMID:
25712187
DOI:
10.2217/pgs.14.166
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center